LAS VEGAS — In this video from Clinical Trials at the Summit, Carl D. Regillo, MD, FACS, discusses the use of tyrosine kinase inhibitors for wet age-related macular degeneration and diabetic retinopathy with diabetic macular edema.
“I think this really holds great promise as a maintenance-based therapy to help decrease the treatment burden in our patients with these common conditions,” Regillo, chief of the retina service at Wills Eye Hospital, told Healio.